Live, 23 - 25 September 2020

Schedule

Create your personal agenda –check the favourite icon

Sep 2313:00
Conference pass

Roundtables

Keynotes
Public policy and the patient voice in defining market access solutions
Sue O'Leary, Vice President, Global Market Access, Prime Global
Roundtable 1: Payer insights and engagement for BeneLux
Francis Arickx, Head Of The Directorate Reimbursement Of Medicines And Pharmaceutical Policy, NIHDI - INAMI Belgium
Roundtable 2: HTA insights and engagement for Italy
Marco Marchetti, Director Of The National Center For Health Technology Assessment, Istituto Superiore di Sanita
Roundtable 3: A tale of two diseases: how orphan drugs can navigate NICE
Josie Godfrey, Director, JG Zebra Consulting
Roundtable 4: Achieving greater appeal for Value Based Agreements
Hassan Bruneo, Associate Director, Alnylam Switzerland Gmbh
Roundtable 5: Using Health Economic Studies to Support Access and Value
Fabrizio Gianfrate, Professor Of Health Economics, Market Access Advisor, Universities of Rome and Ferrara
Roundtable 6: Accelerating access to treatments for rare diseases
Kate Adcock, Director Of Research And Innovation, The Muscular Dystrophy U.K.
Roundtable 7: Does pricing innovative drugs fairly improve your bottomline?
Michael Schroter, Partner, Viopas Partners
Roundtable 8: Exploring Digital Therapeutics
Olaf Schoeman, Head Of Operations And Director, Pharmerit International
Sep 2314:00
Conference pass
Sep 2314:00
Conference pass

Chair’s Opening remarks

Rare Diseases, Big Data, Diagnostics & Digital
Francis Crawley, Executive Director, Strategic Initiative For Developing Capacity In Ethical Review (Sidcer), Good Clinical Practice Alliance (GCPA)
Sep 2314:00
Conference pass

Chair’s Opening remarks

Managed Entry Agreements, HTA & Advanced Therapies
Andrea Mantovani, Former Market Access Executive, Independent
Sep 2314:00
Conference pass

Chair’s Opening remarks

Affordability & Far East
Christina Vandoros, Director, Macroeconomics And Health Policy - Emea, Janssen
Sep 2314:05
Conference pass

Delivering Value Effectively: A German perspective

Evidence & Value
Marco Penske, Head Of Market Access And Health Care Affairs, Boehringer-Ingelheim
Sep 2314:05
Conference pass

Big data & AI in pricing and access to medicines

Rare Diseases, Big Data, Diagnostics & Digital
Francis Crawley, Executive Director, Strategic Initiative For Developing Capacity In Ethical Review (Sidcer), Good Clinical Practice Alliance (GCPA)
Sep 2314:05
Conference pass

Experiences from managed entry agreements

Managed Entry Agreements, HTA & Advanced Therapies
Bart Van Den Daele, Head Of External Affairs - Director Market Access, Gilead Sciences
Sep 2314:05
Conference pass

Political dimensions affecting affordability in the Dutch market

Affordability & Far East
Ulrike Jacobi, Head Of External Affairs And Market Access, Amgen
Sep 2314:20
Conference pass

Exploring value-added medicines

Evidence & Value
Maja Sercic, Policy & Science Manager, Medicines for Europe
Sep 2314:20
Conference pass

Optimal Global Pricing: Resolving with exact numerical solutions two problems - Optimal Launch Pricing and Parallel Trade

Rare Diseases, Big Data, Diagnostics & Digital
Mitch Scurtu, President, Global Technologies
Sep 2314:20
Conference pass

Exploring the use of Managed Entry Agreements in the Middle East

Managed Entry Agreements, HTA & Advanced Therapies
Camille Harfouche, Rare Diseases and Access Lead, Algorithm
Sep 2314:30
Conference pass

Solving the Affordability Challenge – what pharma companies can do beyond philanthropy

Affordability & Far East
John Alter, Vice President Pricing And Market Access, Pfizer
Sep 2314:35
Conference pass

Value considerations in Canada’s new regulatory pricing framework

Evidence & Value
Elena Lungu, Manager Of Policy Development, Government of Canada (Canada)
Sep 2314:35
Conference pass

How transparency in R&D can improve access conditions?

Rare Diseases, Big Data, Diagnostics & Digital
Jaume Vidal, Senior Policy Advisor-European Projects, Health Action International
Sep 2314:35
Conference pass

Interview: What to watch out for in implementing managed entry agreements

Managed Entry Agreements, HTA & Advanced Therapies
Shanthy Krishnaraja, Senior Director, Market Access And Strategy, Seqirus
Sep 2315:05
Conference pass

Roundtables

Keynotes
Roundtable 1: Efficacy to Effectiveness - E2E – translating the promise of clinical trials to the real world
Chris Pashos, Former Vice President Of Global Evidence Strategy, AbbVie
Roundtable 2: Access and HTA considerations for Turkey and Ukraine
Oresta Piniazhko, Director, Hta Department, Ministry of Health of Ukraine
Kagan Atikeler, Researcher, Utrecht University
Roundtable 3: Exploring the value from repurposing drugs: Who Benefits?
Douglas Foerster, Head Market Access, Santhera Pharmaceuticals
Roundtable 4: Exploring challenges and opportunities across Africa on achieving new affordable strategies for Universal Health Coverage
Sagie Pillay, Chief Operating Officer, Wits Health Consortium
Roundtable 5: Exploring innovative reimbursement and payment models for orphan drugs
Jaime Espin, Professor, Andalusian School Of Public Health
Sebastian Soluch, Head Of Market Access And Pricing, Europe, Stemline Therapeutics Inc
Roundtable 6: Market Access and pricing considerations for Spain
Carme Pinyol, Head Of Pricing And Market Access Southern Europe, Pierre Fabre
Jonathan Galduf, Head Of Market Access & Public Affairs, CSL Behring
Roundtable 7: How do you include the patient perspective in a outcomes-based contract?
Girisha Fernando, CEO, Lyfegen HealthTech AG
Jolanda Koenders, Head Of Patient Value And Access, Takeda
Roundtable 8: Perspectives on remote project delivery for global pricing and market access functions: operational aspects and life hacks that ensure market access continuity
James Wright, Director, Valid Insight
Frank Cousins, Senior Director, Valid Insight
Sep 2316:00
Conference pass

Chair’s remarks

Rare Diseases, Big Data, Diagnostics & Digital
Sandro Cesaro-Tadic, Head Pricing I8 And Product Pricing Strategies, Roche
Sep 2316:00
Conference pass

Chair’s remarks

Managed Entry Agreements, HTA & Advanced Therapies
Meindert Boysen, Director of the Centre for Health Technology Evaluation, National Institute for Health and Care Excellence
Sep 2316:00
Conference pass

Chair’s remarks

Biosimilars, Value Added Medicines & Emerging Markets
Robert Orzechowski, Chief Operating Officer, Lancaster Cancer Centre
Sep 2316:05
Conference pass

What does value mean for LMIC countries?

Evidence & Value
Rabia Kahveci, Senior Technical Advisor on Pharmaceutical Policies and Governance, Management Sciences for Health
Sep 2316:05
Conference pass

From Digital To Big Data Analytics & AI In Real World Data

Rare Diseases, Big Data, Diagnostics & Digital
Igor Rudychev, Head of Analytics, Novartis
Sep 2316:05
Conference pass

Exploring payer and implementation considerations for managed entry agreements

Managed Entry Agreements, HTA & Advanced Therapies
Bertrand Tardivel, General Manager, Frehel GmbH
Sep 2316:05
Conference pass

Sustainable market competition for long-term value generation of biosimilar medicines

Biosimilars, Value Added Medicines & Emerging Markets
Diogo Piedade, Market Access Manager, Medicines for Europe
Sep 2316:20
Conference pass

Gene therapies: Beyond a one and done

Evidence & Value
Juan Roman, Vice President, Global Market Access, HEOR and Pricing, Krystal Biotech
Sep 2316:20
Conference pass

Access and pricing considerations in the world of innovative diagnostics

Rare Diseases, Big Data, Diagnostics & Digital
Benjamin Gannon, Vice President International Access, Policy And Advocacy, Myriad genetics
Sep 2316:20
Conference pass

Achieving the best outcomes when negotiating managed entry agreements

Managed Entry Agreements, HTA & Advanced Therapies
Inneke Van De Vijver, Strategic Advisor - Reimbursement Pharmaceuticals, N.I.H.D.I.
Sep 2316:20
Conference pass

Market access for value added medicines in Europe

Biosimilars, Value Added Medicines & Emerging Markets
Olga Diachenko, Market Access Manager Europe, Accord Healthcare
Sep 2316:35
Conference pass

What does value mean for a private payer?

Evidence & Value
Charles De Cidrac, Director Of Health Insurance, AXA
Sep 2316:35
Conference pass

Diabetes care in the world of digital health: What does the evidence suggest?

Rare Diseases, Big Data, Diagnostics & Digital
Sep 2316:35
Conference pass

The patient perspective in managed entry agreements

Managed Entry Agreements, HTA & Advanced Therapies
Rob Burley, Director Of Campaigns, Care And Support, The Muscular Dystrophy U.K.
Sep 2316:35
Conference pass

A look at legislation for Biosimilars in Germany

Biosimilars, Value Added Medicines & Emerging Markets
Michael Ermisch, Specialist, Department Of Pharmaceuticals, G.K.V. Spitzenverband
Sep 2317:05
Conference pass

Chair’s remarks

Pricing and Market Access & Government Affairs
Gundula Schneidewind, Head Ethics And Compliance, Europe And Canada, Takeda
Sep 2317:05
Conference pass

Chair’s remarks

Rare Diseases, Big Data, Diagnostics & Digital
Chris Wasden, Head of HappifyDTx, Happify Health
Sep 2317:05
Conference pass

Chair’s remarks

Patient Advocacy & Payer Engagement
Dawn Torrence Ireland, President And Founder, C.H.E.R.U.B.S.
Sep 2317:05
Conference pass

Chair’s remarks

Contracting, Price Tendering & Payer Communications
Diar Fattah, Global Director, Innovative Value Strategies And Evidence (Respiratory), AstraZeneca
Sep 2317:10
Conference pass

New developments in Poland for pricing & reimbursement

Pricing and Market Access & Government Affairs
Marcin Czech, Former Vice Minister, Ministry of Health Poland
Sep 2317:10
Conference pass

Digital Medicines: Where are we now and what next

Rare Diseases, Big Data, Diagnostics & Digital
Oliver Gassner, Head G4A Digital Health Intelligence Emea, Bayer
Sep 2317:10
Conference pass

Interview: The Importance of patient advocacy and the challenge of financial toxicity

Patient Advocacy & Payer Engagement
Robert Orzechowski, Chief Operating Officer, Lancaster Cancer Centre
Hyatt DeGreen, President, LANCASTER CANCER CENTER
Sep 2317:10
Conference pass

Opportunities of regional and national contracting in Germany

Contracting, Price Tendering & Payer Communications
Fabrizio Zucca, Director Market Access Dach, Intercept Pharmaceuticals Inc
Sep 2317:25
Conference pass

Governmental policy in the healthcare industry across the Middle East

Pricing and Market Access & Government Affairs
Rita Shorjian, Market Access Head - Near East And North West Africa, AbbVie
Sep 2317:25
Conference pass

Interview: Creating an evidence strategy from the perspective of a digital therapeutic start-up

Rare Diseases, Big Data, Diagnostics & Digital
Sven Jungmann, Co-Founder, FoundersLane
Sep 2317:25
Conference pass

Industry and patients working together for better access

Patient Advocacy & Payer Engagement
Mary Lynne Van Poelgeest-Pomfret, President, President of the World Federation for Incontinence and Pelvic Pain - WFIP
Sep 2317:25
Conference pass

How to build and communicate a convincing customer value proposition in tendering

Contracting, Price Tendering & Payer Communications
Nico Bacharidis, Former Global Tender Lead And Founder Of Growpal, Pfizer
Sep 2317:40
Conference pass

Insight into US Government Policy and Payer strategy

Pricing and Market Access & Government Affairs
Erin Mistry, SVP, Head of Payer Strategy, Gov’t Affairs and Trade Relations, CorMedix Inc
Sep 2317:40
Conference pass

Using a digital pricing and market access simulator App to enhance product development

Rare Diseases, Big Data, Diagnostics & Digital
Raf De Wilde, Senior Executive Advisor, Valid Insight
Sep 2317:40
Conference pass

The value provided to pharma through patient advocacy – hard lessons learnt from industry

Patient Advocacy & Payer Engagement
Nadia Bodkin, Rare Disease Advocacy Professional, Rare Advocacy Movement
Sep 2317:40
Conference pass

Multi-, Cross-, Omni-Channel Evolution in Payer Communications

Contracting, Price Tendering & Payer Communications
Stephanie Chen, Associate Director, Global Access Marketing Oncology, Bayer

Create your personal agenda –check the favourite icon

Sep 2409:55
Conference pass
Sep 2410:00
Conference pass

Innovation in industry and practical considerations for biotechs

Keynotes
Erik Van Den Berg, Chief Executive Officer, A.M. Pharma
Sep 2410:20
Conference pass

Trends in modelling approaches for successful reimbursement of ATMPs

Keynotes
Ion Agirrezabal, Senior Consultant, Covance Market Access And Phase Iv Solutions, Covance Market Access
Sep 2410:40
Conference pass

Interview: Unleash the Algorithms: Critical Success Factors to Reinvent Our Role in Delivering Patient Value

Keynotes
Dr Bharat Tewarie, Founder & CEO Boston BioPharma Consultants/ Former EVP& Chief Marketing Officer, UCB, Boston BioPharma Consultants
Sep 2411:00
Conference pass

Around the world in 80 MEAs

Keynotes
Ezequiel Heredia, Consultant, Lifescience Dynamics Ltd
Sep 2411:20
Conference pass

Embracing competition to deliver the true value of biosimilars

Keynotes
Isabell Remus, Head Biopharmaceuticals Europe, Sandoz
Sep 2412:00
Conference pass

Roundtables

Keynotes
Roundtable 10: Branded combo-pricing: Where too next?
Yves Samel, Market Access Strategy Leader And Global Pricing Manager, Bayer
Roundtable 11: New HTA requirements in France: impact of unmet need on access
Delphine Houzelot, VP Market Access, Prioritis Market Access
Roundtable 1: Open
Roundtable 2: Pricing Strategy – What to Do and When?
Andreia Ribeiro, Director, Lifescience Dynamics Ltd
Roundtable 3: Exploring reimbursement models: Working with external stakeholders to improve outcomes
Gomathi Kaliappan, Global Market Access - Health Systems Strategy, Value Recognition, Roche
Roundtable 4: Challenges associated with communicating the value of Cell & Gene Therapies
Roundtable 5: HTA developments across Eastern Europe
Tatyana Benisheva, Professor In Drug Regulatory Affairs, Bulgarian Association for Drug Information
Roundtable 6: What if you could listen to 1,000,000,000 authentic patient voices? Turning real-world conversations into evidence
Roundtable 7: Patient based generated evidence
Caridad Pontes, Manager Of Pharmacotherapeutic Harmonization, Catalan Health Service
David Elvira, Heads Eu Public Affairs, Sanofi
Roundtable 8: Achieving greater collaboration amongst payers, HTAs, pharma and patients to improve outcomes
Jost Leemhuis, Head Of Safety Science, Roche
Roundtable 9: Advanced Therapies: The role of registries in convincing payers about long-term effects
Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (Belgium)
Sep 2412:45
Conference pass

Chair’s Remarks

Keynotes
Navin Joshi, Global Head Of Pricing, Classic And Established Products. Global Pharma, Head Of Pricing And Access Capabilities, Emerging Marke, GlaxoSmithKline
Sep 2412:50
Conference pass

Interview: Orphan Drugs, Gene Therapies, Post-Marketing-Data: Latest developments in German legal framework for drug assessment and reimbursement

Keynotes
Thomas Mueller, Head Of Directorate General 1 - Drugs, Medical Devices, Biotechnology, Federal Ministry of Health Germany
Sep 2413:10
Conference pass

Virtual Research: What it Is & What it’s Doing in the Real-World Setting

Keynotes
Sep 2413:30
Conference pass

Interview: Reflections on Medical Innovations in the time of COVID-19 Pandemic

Keynotes
Ryan Saadi, CEO, Tevogen Bio
Sep 2414:10
Conference pass

Chair’s remarks

Evidence & Value
Chris Pashos, Former Vice President Of Global Evidence Strategy, AbbVie
Sep 2414:10
Conference pass

Chair’s remarks

Pricing and Market Access & Government Affairs
Gustavo Saraiva Dos Anjos, Global Market Access Director For Biologics, GlaxoSmithKline
Sep 2414:10
Conference pass

Chair’s remarks

Rare Diseases, Big Data, Diagnostics & Digital
Lisette Kaskens, Senior Global Market Access Manager, Advanced Accelerator Applications
Sep 2414:10
Conference pass

Chair’s remarks

Managed Entry Agreements, HTA & Advanced Therapies
Reg Waldeck, Oncology Market Access Strategy Leader, Bayer Corp
Sep 2414:10
Conference pass

Chair’s remarks

Affordability & Far East
Mark Chalmers, Director, Navigant – A Guidehouse Company
Sep 2414:15
Conference pass

Can Pharma save $1 billion through the strategic use of RWE?

Evidence & Value
Melvin Olson, Global Head Rwd Strategy And Innovation, Novartis Pharma
Sep 2414:15
Conference pass

Lessons learnt in implementing an outcomes based contract

Pricing and Market Access & Government Affairs
Diar Fattah, Global Director, Innovative Value Strategies And Evidence (Respiratory), AstraZeneca
Sep 2414:15
Conference pass

Patient access to rare disease treatments: Insights from industry

Rare Diseases, Big Data, Diagnostics & Digital
Jolanda Koenders, Head Of Patient Value And Access, Takeda
Sep 2414:15
Conference pass

Horizon scanning in the HTA process; helping to facilitate UK market access

Managed Entry Agreements, HTA & Advanced Therapies
Dapo Ogunbayo, Programme Manager - Healthcare Innovations (Pharmaceuticals), NIHR Innovation Observatory, Newcastle University
Sep 2414:15
Conference pass

Market access conditions and healthcare for the Far East and Australasia

Affordability & Far East
Diane Munch, Vice President, Global Pricing, Patient And Health Impact, Pfizer
Samuel Taylor, Emerging Markets Pricing Lead, Pfizer
Sep 2414:30
Conference pass

RWE for regulatory and HTA decision-making: latest precedent and what's ahead

Evidence & Value
Ashley Jaksa, VP Analytic Solutions, Aetion, Inc.
Sep 2414:30
Conference pass

Outcome-Based contracts and other innovative pricing models: Expectation or reality?

Pricing and Market Access & Government Affairs
Sep 2414:30
Conference pass

Patient Access for Rare Disease – A HTA Perspective

Rare Diseases, Big Data, Diagnostics & Digital
Ruth Howells, Practice Leader, VP, Clarivate Analytics
Sep 2414:30
Conference pass

EUnetHTA Joint Assessments and Implications for the Industry

Managed Entry Agreements, HTA & Advanced Therapies
Sep 2414:30
Conference pass

Breaking down the ‘Great Wall’: do the evolving market access policy dynamics in China represent the next big opportunity of Pharma?

Affordability & Far East
Amy Wang, Managing Consultant, Guidehouse
Sep 2414:45
Conference pass

Effective RWE strategy for regulatory approval and reimbursement

Evidence & Value
Nneka Onwudiwe, Founder And Chief Executive Officer, Pharmaceutical Economics Consultants of America (PECA) LLC
Sep 2414:45
Conference pass

Interview: Value-based Contracting Status and Outlook

Pricing and Market Access & Government Affairs
Birgit Holz, Global Head Of Contracting Innovation, Sanofi
Sep 2414:45
Conference pass

The continuing changing landscape in creating value beyond price for rare disease products in the US

Rare Diseases, Big Data, Diagnostics & Digital
Diann Potestio, Vice President Market Access, Ascendis Pharma
Sep 2414:45
Conference pass

Insight on HTA in Ukraine

Managed Entry Agreements, HTA & Advanced Therapies
Oresta Piniazhko, Director, Hta Department, Ministry of Health of Ukraine
Sep 2414:45
Conference pass

Bringing accessibility and affordability to scale in the next decade

Affordability & Far East
Marijn Verhoef, Engagement Manager, Access to Medicine Foundation
Sep 2415:15
Conference pass

Chair’s remarks

Evidence & Value
Angelina Irizari Policarpio, Head of HEOR and RWE Field Communications Team, Eisai
Sep 2415:15
Conference pass

Chair’s remarks

Pricing and Market Access & Government Affairs
Sep 2415:15
Conference pass

Chair’s remarks

Rare Diseases, Big Data, Diagnostics & Digital
Sep 2415:15
Conference pass

Chair’s remarks

Managed Entry Agreements, HTA & Advanced Therapies
Andreia Ribeiro, Director, Lifescience Dynamics Ltd
Sep 2415:15
Conference pass

Chair’s remarks

Biosimilars, Value Added Medicines & Emerging Markets
Kevin Loth, Former Vice President, Corporate Affairs And Policy, Worldwide Markets, Celgene
Sep 2415:20
Conference pass

Use of RWE in oncology

Evidence & Value
Fabrizio Gianfrate, Professor Of Health Economics, Market Access Advisor, Universities of Rome and Ferrara
Sep 2415:20
Conference pass

Market access for gene therapies in Germany

Pricing and Market Access & Government Affairs
Axel Boehnke, Director Market Access Eu North, PTC Therapeutics
Sep 2415:20
Conference pass

The impact of COVID-19 on funding for rare disease research

Rare Diseases, Big Data, Diagnostics & Digital
Dawn Torrence Ireland, President And Founder, C.H.E.R.U.B.S.
Sep 2415:20
Conference pass

Understanding and engaging with HTA in Russia

Managed Entry Agreements, HTA & Advanced Therapies
Nuriya Musina, Head Of Development, Federal State Budgetary Institution, The Center For Healthcare Quality Assessme, Ministry of Health Russian Federation
Sep 2415:20
Conference pass

Challenges for reimbursement and innovation in Latin

Biosimilars, Value Added Medicines & Emerging Markets
Giovanny Leon, P&Ma Director, Novartis Ag
Sep 2415:35
Conference pass

Integrating evidence effectively into a viable commercial strategy

Evidence & Value
Ali Ciger, Commercial Director, Pain, Pfizer
Sep 2415:35
Conference pass

Future Trends - How Payers in the US and Europe are adapting to the ATMP revolution

Pricing and Market Access & Government Affairs
Herve Lilliu, Chief Executive Officer, inbeeo
Sep 2415:35
Conference pass

Innovative reimbursement and payment models for orphan drugs

Rare Diseases, Big Data, Diagnostics & Digital
Jaime Espin, Professor, Andalusian School Of Public Health
Sep 2415:35
Conference pass

Understanding risk-sharing agreements and post-reimbursement evaluation in South Korea

Managed Entry Agreements, HTA & Advanced Therapies
Jeonghoon Ahn, Former Director, National Evidence-based Healthcare Collaborating Agency
Sep 2415:35
Conference pass

Exploring commercial strategies in orphan drugs in the public healthcare system in Argentina

Biosimilars, Value Added Medicines & Emerging Markets
Marcelo Sal, Head of Market Access and Pricing, Argentina, PTC Therapeutics
Sep 2415:50
Conference pass

Latest developments in evidence for oncology

Evidence & Value
Reg Waldeck, Oncology Market Access Strategy Leader, Bayer Corp
Sep 2415:50
Conference pass

Adopting a patient centric approach to access for gene therapies

Pricing and Market Access & Government Affairs
Nanxin (Nick) Li, Senior Director and Head, Health Economics and Outcomes Research (HEOR), uniQure
Sep 2415:50
Conference pass

Joint assessment for orphan drugs: Insight from EUnetHTA

Rare Diseases, Big Data, Diagnostics & Digital
Anne Willemsen, Project Manager Eunethta, Zorginstituut Nederland / EUnetHTA
Sep 2415:50
Conference pass

The DIVE framework: how to incorporate all information into your estimation process: Direct evidence, Indirect evidence, validation and external information incorporation?

Managed Entry Agreements, HTA & Advanced Therapies
Mario Ouwens, Senior Statistical Science Director, Astra Zeneca
Sep 2415:50
Conference pass

The link between HTA and decision-making in resource allocation

Biosimilars, Value Added Medicines & Emerging Markets
Andres Pichon Riviere, Executive Director And Director Of Health Technology Assessment And Economic Evaluations, I.E.C.S.
Sep 2416:20
Conference pass

Roundtables

Keynotes
Roundtable 10: Capability building for RWE
Angelina Irizari Policarpio, Head of HEOR and RWE Field Communications Team, Eisai
Elena Panitti, Global Rwe Capability Building Lead, Novartis
Roundtable 12: Virtual approaches for real-world research
Roundtable 1: HTA: to collaborate or not? Secrets of partnering success
Akshay Kumar, Partner, Partners4Access
Francesca Cook, Senior Director, Global Head Of Pricing And Market Access, Regenxbio
Roundtable 2: Developments in pricing and patient access for speciality treatments
Jenny Ebert, National Account Director, Ascendis Pharma
Keith White, Vice President And Head, Global Market Access, Corbus Pharmaceuticals
Roundtable 3: Oncology drug market: a high-growth, high-price therapeutic area
Elena Lungu, Manager Of Policy Development, Government of Canada (Canada)
Roundtable 4: The Modeling Impact of Policy Decisions on Pricing
Alan Crowther, General Manager, EVERSANA
Roundtable 5: Innovative and Value Based Agreements – more of the same, or solution for access?
Julien Patris, Director Market Access & Policy – Europe / Canada / MEA (CEMEA), Alnylam
Roundtable 6: Pricing Competition from Launch to Loss of Exclusivity
Adam Plich, Managing Director, Plich Advisory
Roundtable 7: Exploring access and pricing challenges for low to middle income countries
Marijn Verhoef, Engagement Manager, Access to Medicine Foundation
Giovanny Leon, P&Ma Director, Novartis Ag
Roundtable 8: Access and pricing considerations for CAR-T development
Nuno Prego Ramos, Chief Executive Officer, Cellmabs
Roundtable 9: The use of real-world evidence to support outcomes-based pricing and reimbursement decisions: opportunities and challenges
Dimitrios Tsourougiannis, Senior Hemar Manager, Janssen - Cilag Ltd
Ahmed Elsada, Health Economics, Market Access and Reimbursement Manager, Janssen
USA and International Reference Pricing – what will happen to confidential discounts in Europe?
Daniel Suhr, Chief Executive Officer, Two Scenarios
Sep 2417:00
Conference pass

Chair’s remarks

Evidence & Value
Fabrizio Gianfrate, Professor Of Health Economics, Market Access Advisor, Universities of Rome and Ferrara
Sep 2417:00
Conference pass

Chair’s remarks

Pricing and Market Access & Government Affairs
Anastasiya Stepanova, GR Manager, S.T.A.D.A.
Sep 2417:00
Conference pass

Chair’s remarks

Rare Diseases, Big Data, Diagnostics & Digital
Josie Godfrey, Director, JG Zebra Consulting
Sep 2417:00
Conference pass

Chair’s remarks

Patient Advocacy & Payer Engagement
Kart Veliste, Chief Specialist At Department Of Medicines And Medical Devices, Haigekassa Estonia
Sep 2417:00
Conference pass

Chair’s remarks

Biosimilars, Value Added Medicines & Emerging Markets
Navin Joshi, Global Head Of Pricing, Classic And Established Products. Global Pharma, Head Of Pricing And Access Capabilities, Emerging Marke, GlaxoSmithKline
Sep 2417:05
Conference pass

Insights into the implementation of HTA recommendations: Understanding the evidence

Evidence & Value
Belen Corbacho, Health Economist, University of York
Sep 2417:05
Conference pass

The Swedish market: Supporting regional payers in managed introduction and prioritisation of new drug therapies

Pricing and Market Access & Government Affairs
Sep 2417:05
Conference pass

Looking at the role of patient advocacy in pricing policies

Rare Diseases, Big Data, Diagnostics & Digital
Francois Houyez, Treatment Information And Access Director, Health Policy Advisor, EURORDIS
Sep 2417:05
Conference pass

Interview: Policy and the Pandemic: Biopharmaceutical Policy and Legislative Priorities in Addressing Innovation, Pricing, Spending and Affordability, Past, Present and Future

Patient Advocacy & Payer Engagement
Robert Popovian, Vice President Of Government Relations, Pfizer
Sep 2417:05
Conference pass

Market access and pricing conditions across the Middle East and Africa

Biosimilars, Value Added Medicines & Emerging Markets
Ayman Semaan, Market Access, Algorithm
Sep 2417:20
Conference pass

Evidence generation across different therapeutic areas

Evidence & Value
Enkeleida Nikai, Head Of Real World Evidence, Senior Director At Janssen Europe, Middle East And Africa (Emea), Janssen Pharmaceutical
Sep 2417:20
Conference pass

Developments in Canadian Pharmaceutical Pricing and Market Access

Pricing and Market Access & Government Affairs
Sep 2417:20
Conference pass

Value Based Healthcare: delivering value to hemophilic patients

Rare Diseases, Big Data, Diagnostics & Digital
Lara Pippo, Head Of Market Access, CSL Behring
Sep 2417:20
Conference pass

Understanding the payer assessment process in Norway

Patient Advocacy & Payer Engagement
Einar Andreassen, Head of unit, HTA and Reimbursement, Norwegian Medicines Agency
Sep 2417:20
Conference pass

Pharmaceutical Pricing Policy and Access in South Africa, A Funder’s Perspective – Key Focus on Rare Diseases

Biosimilars, Value Added Medicines & Emerging Markets
Inez Naidu, Head - Discovery Health Medicines Unit, Discovery Health
Noluthando Nematswerani, Head - Centre For Clinical Excellence, Discovery Health
Sep 2417:35
Conference pass

Looking at the evidence after launch: addressing access hurdles across different markets

Evidence & Value
Rasmus Jensen, Global Head Of Market Access, Camurus
Sep 2417:35
Conference pass

Market access developments for Russia

Pricing and Market Access & Government Affairs
Daria Tolkacheva, Head Of Health Economics, JSC BIOCAD
Valentin Dodonov, Deputy General Head Of Market Access, Biocad
Sep 2417:35
Conference pass

The Hercules Project: Patient-led Access in Rare Diseases

Rare Diseases, Big Data, Diagnostics & Digital
Josie Godfrey, Director, JG Zebra Consulting
Sep 2417:35
Conference pass

What is the value of the patient’s perspective when negotiating with payers?

Patient Advocacy & Payer Engagement
Andrea Mantovani, Former Market Access Executive, Independent
Sep 2417:35
Conference pass

The Sanofi Espoir Foundation- improving access in Africa

Biosimilars, Value Added Medicines & Emerging Markets
Valerie Faillat, Head Of Sanofi Espoir Foundation, Sanofi

Create your personal agenda –check the favourite icon

Sep 2508:55
Conference pass

Chair’s opening remarks

Keynotes
Gustavo Saraiva Dos Anjos, Global Market Access Director For Biologics, GlaxoSmithKline
Sep 2509:00
Conference pass

Market Access considerations from NICE

Keynotes
Carla Deakin, Programme Director - Commercial And Managed Access, NICE
Tamir Singer, Head Of Commercial Development, Specialised Commissioning, NHS England
Sep 2509:20
Conference pass

Trends in HTA Decisions for Oncology, Single & Combination Therapies

Keynotes
Alan Crowther, General Manager, EVERSANA
Magdi Stino, Product Manager, EVERSANA
Sep 2509:40
Conference pass

Achieving greater stakeholder engagement to improve patient and payer related outcomes

Keynotes
What key initiatives are helping to improve cooperation among payers, patients and manufacturers?What innovation is taking place in contracting?What suggestions would you offer to streamline contracting arrangements and improve patient & payer outcomes?
Gustavo Saraiva Dos Anjos, Global Market Access Director For Biologics, GlaxoSmithKline
Ulf Staginnus, Senior Vice President, Head Of Global Market Access And Pricing, Ipsen Pharma
Andreia Ribeiro, Director, Lifescience Dynamics Ltd
Ulrike Jacobi, Head Of External Affairs And Market Access, Amgen
Evert Jan Van Lente, Director Eu-Affairs, AOK Bundesverdand
Tamir Singer, Head Of Commercial Development, Specialised Commissioning, NHS England
Sep 2511:00
Conference pass

Roundtables

Keynotes
Roundtable 1: Innovation in Contracting
Fabrizio Zucca, Director Market Access Dach, Intercept Pharmaceuticals Inc
Birgit Holz, Global Head Of Contracting Innovation, Sanofi
Roundtable 2: Risk-sharing arrangements: Are they improving patient access to new medicines?
Catarina Lopes Pereira, Global Market Access Manager, Medac
Roundtable 3: Exploring Biosimilars in the USA and Europe – latest developments
Sue Naeyaert, Advisor, Independent
Roundtable 4: How to establish a market access department from scratch?
Michael Muller, Head Of Market Access, Western Europe, Sun Pharma
Roundtable 5: Evidence solutions and CAR-T
Clare Hague, Therapy Area Market Access Lead, Hematology, Janssen Pharmaceutical
Roundtable 6: Exploring the international reference pricing landscape
Tanya Aiden, Global Products Lead, BIOCAD
Roundtable 7: Market access, Pricing, Payer & HTA developments for the Nordic Region
Einar Andreassen, Head of unit, HTA and Reimbursement, Norwegian Medicines Agency
Dorthe Bartels, Strategic Adviser, Amgros
Roundtable 8: Real world data and its utility in HTA decisions
Madhusudan Kabra, Director, Evidence Generation, Otsuka Pharmaceutical
Roundtable 9: Exploring HTA requirements and novel payment methods for anti-biotics
Warren Cowell, Director Market Access UK, Shionogi Ltd
Sep 2512:00
Conference pass

Chair’s remarks

Evidence & Value
Kevin Rieger, Head Of Public And Governmental Affairs Dach, Ipsen Pharma Gmbh
Sep 2512:00
Conference pass

Chair’s remarks

Pricing and Market Access & Government Affairs
David Watson, Executive Director, Economic, Health and Commercial Policy, ABPI
Sep 2512:00
Conference pass

Chair’s remarks

Rare Diseases, Big Data, Diagnostics & Digital
Ines Alves, President, ANDO Portugal
Sep 2512:00
Conference pass

Chair’s remarks

Managed Entry Agreements, HTA & Advanced Therapies
Bertrand Tardivel, General Manager, Frehel GmbH
Sep 2512:05
Conference pass

Real world evidence in the era of COVID-19: Reflections from Russia

Evidence & Value
Anastasiya Stepanova, GR Manager, S.T.A.D.A.
Sep 2512:05
Conference pass

Governance in the world of access and pricing

Pricing and Market Access & Government Affairs
Claudia Neuber, Head Of Global Pricing Implementation, AstraZeneca
Sep 2512:05
Conference pass

Innovation in treating rare diseases: HTA approach in Scotland

Rare Diseases, Big Data, Diagnostics & Digital
Mark Macgregor, Medical Director, Golden Jubilee National Hospital
Sep 2512:05
Conference pass

Understanding the advanced therapy landscape and beyond: an investors perspective

Managed Entry Agreements, HTA & Advanced Therapies
Michael Schroter, Partner, Viopas Partners
Sep 2512:20
Conference pass

Value Evidence Generation in Product Lifecycle Management of Medical Technologies: Fit for Purpose, Fit for Future?

Evidence & Value
Luqman Tariq, Market Access Director, Europe, Stryker Corp
Sep 2512:20
Conference pass

Exploring the development of international reference pricing across different jurisdictions

Pricing and Market Access & Government Affairs
Matt Slabbert, Chief Coordinator – Patient Access Policy & UHC, Bayer Pharmaceuticals
Sep 2512:20
Conference pass

Cross indication pricing considerations for gene therapy

Managed Entry Agreements, HTA & Advanced Therapies
Alex Grosvenor, Senior Vice President, PRECISIONadvisors
Sep 2512:25
Conference pass

Early Access to treatment for Rare Disease patients

Rare Diseases, Big Data, Diagnostics & Digital
Rute Fernandes, Head Of Rare Diseases Of Europe And Canada, Takeda
Sep 2512:35
Conference pass

The use of RWE in patient support programs

Evidence & Value
Priyal Sheth, Neuroscientist & VP of Business Development, Q1.6
Sep 2512:35
Conference pass

US insights: Alternative payment methodologies

Pricing and Market Access & Government Affairs
Ed Pezalla, Former Vice President, National Medical Director For Pharmaceutical Policy And Strategy, Aetna; a CVS Pharmacy Health Company
Sep 2512:35
Conference pass

Exploring repurposed products for rare diseases

Rare Diseases, Big Data, Diagnostics & Digital
Amer Omar, Senior Director, Lupin
Sep 2512:35
Conference pass

Risk sharing agreements for cell and gene therapies

Managed Entry Agreements, HTA & Advanced Therapies
Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (Belgium)
Sep 2513:05
Conference pass

Roundtables

Keynotes
Roundtable 1: Accelerating Access to treatments for Rare Diseases
Gina Ewy, Head Of Global Market Access, Hansa Biopharma
Roundtable 2: Exploring High Cost Novelty Medicine Access and HTA in South Africa
Niri Bhimsan, Head - Health Technology Assessment, Discovery Health
Inez Naidu, Head - Discovery Health Medicines Unit, Discovery Health
Roundtable 3: Opportunities & Challenges for Collection of RWD in Early Access Programs (EAPs)
Alastair Macdonald, Senior Vice President Of Real World And Late Phase, Syneos Health
Roundtable 4: Industry and patients working together for better access
Mary Lynne Van Poelgeest-Pomfret, President, President of the World Federation for Incontinence and Pelvic Pain - WFIP
Roundtable 5: Modelling the value of digital health innovations
Roundtable 6: The Modeling Impact of Policy Decisions on Pricing
Alan Crowther, General Manager, EVERSANA
Roundtable 7: What if you could listen to 1,000,000,000 authentic patient voices? Turning real-world conversations into evidence
Roundtable 8: Understanding Business Challenges of Shifting IV drugs to SC to Enable Self-delivery
Marie-Liesse Le Corfec, Global Portfolio Marketing Head, Ps, B.D. Pharmaceuticals Systems
Alfred Harvey, Associate Director, Health Economics And Outcomes Research, Becton Dickinson
Roundtable 9: Achieving the best outcomes when negotiating managed entry agreements
Inneke Van De Vijver, Strategic Advisor - Reimbursement Pharmaceuticals, N.I.H.D.I.
Sep 2514:05
Conference pass

Chair’s remarks

Evidence & Value
Ramon Hernandez Vecino, Head Of Real World Evidence Data And Analytics Engagement Lead Randd, Sanofi
Sep 2514:05
Conference pass

Chair’s remarks

Pricing and Market Access & Government Affairs
Anne Marciniak, Head Of Market Access, Europe, Aimmune
Sep 2514:05
Conference pass

Chair’s remarks

Rare Diseases, Big Data, Diagnostics & Digital
Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (Belgium)
Sep 2514:05
Conference pass

Chair’s remarks

Managed Entry Agreements, HTA & Advanced Therapies
Adam Heathfield, Senior Director Of Global Health And Value Innovation Centre, Pfizer Ltd
Sep 2514:10
Conference pass

Developing capabilities to support effective evaluation of data

Evidence & Value
Sue Naeyaert, Advisor, Independent
Sep 2514:10
Conference pass

Exploring challenges and opportunities across South Africa on achieving new affordable strategies for Universal Health Coverage

Pricing and Market Access & Government Affairs
Sagie Pillay, Chief Operating Officer, Wits Health Consortium
Sep 2514:10
Conference pass

The incentives’ review by the EU Commission and its implication on OMPs

Rare Diseases, Big Data, Diagnostics & Digital
Ana Palma, Senior Director Global Hta And Patient Access Lead, Sobi
Sep 2514:10
Conference pass

A manufacturer’s move to patient-centricity

Managed Entry Agreements, HTA & Advanced Therapies
Scott Doyle, Senior Director, TA Head, Astellas
Sep 2514:25
Conference pass

Develop robust RWE Analytics Capability to enable rapid evidence generation

Evidence & Value
Yonghua Jing, Director, Real World Evidence & Analytics, Health Economics & Outcomes Research, AbbVie
Sep 2514:25
Conference pass

New HTA - regulations for Orphan drugs in Germany

Rare Diseases, Big Data, Diagnostics & Digital
Antje Behring, Acting Head, Federal Joint Committee
Sep 2514:25
Conference pass

Perspectives from the Alliance for Regenerative Medicine: improving access to cell and gene therapies

Managed Entry Agreements, HTA & Advanced Therapies
Sep 2514:35
Conference pass

Interview: Achieving greater collaboration with HTAs: Insights from EUnetHTA

Pricing and Market Access & Government Affairs
Marcus Guardian, Chief Operating Officer, EUnetHTA
Sep 2514:40
Conference pass

The role of real-world evidence in establishing optimal access for an orphan disease

Evidence & Value
Anindita Sinha, Pipeline Lead, US Market Access, Immunology, Boehringer Ingelheim
Sep 2514:40
Conference pass

Where do we go from here - bridging the gap from regulatory approval to market access using MoCA

Rare Diseases, Big Data, Diagnostics & Digital
Anna Bucsics, Project Advisor, Mechanism of Coordinated Access to orphan medicinal products (MoCA)
Sep 2514:40
Conference pass

Looking at Value for Advanced Therapies in Quebec

Managed Entry Agreements, HTA & Advanced Therapies
Luc Boileau, Chairman And Chief Executive Officer, INESSS
Sep 2515:40
Conference pass

Chair’s remarks

Evidence & Value
Wim Goettsch, Special Hta-Advisor, Zorginstituut
Sep 2515:40
Conference pass

Chair’s remarks

Pricing and Market Access & Government Affairs
Hanadi Nahas, Chairman And General Manager, Access Core
Sep 2515:40
Conference pass

Chair’s remarks

Rare Diseases, Big Data, Diagnostics & Digital
Sheela Upadhyaya, Rare Disease Expert, National Institute for Health and Care Excellence
Sep 2515:40
Conference pass

Chair’s remarks

Managed Entry Agreements, HTA & Advanced Therapies
Sep 2515:45
Conference pass

Real-world evidence and the 2020 NICE Methods Update

Evidence & Value
Micah Rose, Senior Scientific Adviser - Health Economic Modelling, NICE Scientific Advice
Sep 2515:45
Conference pass

Drivers of preference for prefilled syringes for anaesthesia/ICU drugs in British, French and German hospitals

Pricing and Market Access & Government Affairs
Marie-Liesse Le Corfec, Global Portfolio Marketing Head, Ps, B.D. Pharmaceuticals Systems
Sep 2515:45
Conference pass

Working with stakeholders to improve access to rare disease treatments

Rare Diseases, Big Data, Diagnostics & Digital
Natasa Zibelnik, Global Head Of Market Access, EUSA Pharma
Sep 2516:00
Conference pass

Using RWE to support innovative contracting

Evidence & Value
Lotte Steuten, Vice President And Head Of Consulting, Office of Health Economics
Sep 2516:00
Conference pass

The role of pharmacy in Patient Support Programs

Pricing and Market Access & Government Affairs
Andrew Lane, Chair, National Pharmacy Association
Sep 2516:00
Conference pass

Achieving greater collaboration to improve access to rare disease treatments and to improve outcomes for patients

Rare Diseases, Big Data, Diagnostics & Digital
Kevin Loth, Former Vice President, Corporate Affairs And Policy, Worldwide Markets, Celgene
Sep 2516:00
Conference pass

Key considerations of the health technology assessment of CAR-Ts in Europe

Managed Entry Agreements, HTA & Advanced Therapies
Renske Ten Ham, Researcher, Utrecht University
Sep 2516:15
Conference pass

Registries for orphan drugs in the German AMNOG process

Evidence & Value
Friedhelm Leverkus, Director Health Technology Assessment And Outcomes Research, Pfizer
Sep 2516:15
Conference pass

Latest insights on patient support programmes across the Middle East

Pricing and Market Access & Government Affairs
Hanadi Nahas, Chairman And General Manager, Access Core
Sep 2516:15
Conference pass

Bridging the Gap between Payers, Patients & the Advocates Navigating Access to Care

Rare Diseases, Big Data, Diagnostics & Digital
Elizabeth Johnson, Biologics Coordinator, Allergy Partners, P.A.
Sep 2516:15
Conference pass

Access and Pricing considerations for CAR-T

Managed Entry Agreements, HTA & Advanced Therapies
Nuno Prego Ramos, Chief Executive Officer, Cellmabs
last published: 19/Sep/20 18:55 GMT

Contact us

To sponsor or exhibit:
Edmond Rama
+44 (0)207 092 1052

edmond.rama@terrapinn.com

To speak:
Chris Shanks
+44 (0)207 092 1151

chris.shanks@terrapinn.com